Although no mechanistic experiments were included, the authors proposed that statins’ inhibition of HMG-CoA reductase and downstream prenylation pathways may enhance chemotherapy sensitivity or modulate tumor-related inflammation. The gene discussed is HMGCR; the disease is neoplasm.